LAUSANNE, Switzerland, and MALVERN, Pennsylvania, September 7, 2011 /PRNewswire/ --
Debiopharm Group™ (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Ascenta Therapeutics, Inc. (Ascenta), a privately-held, biopharmaceutical company dedicated to the discovery and development of new medicines to treat cancer, have entered into an exclusive worldwide license agreement concerning the development and commercialization of AT-406 (called Debio 1143 by Debiopharm) a small molecule IAP inhibitor currently in phase I development. By targeting inhibitors of apoptosis proteins, AT-406 (or Debio 1143) can induce cancer cell death and/or potentiate the efficacy of other treatments and is expected to be effective in the treatment of various cancers in combination with anti-cancer therapies.
"We are very excited about this collaboration with Ascenta Therapeutics. This company has an impressive scientific team and expertise in the field of apoptosis", said Dr Rolland-Yves Mauvernay, president and founder of Debiopharm S.A., who added "it should be possible to combine AT-406 (or Debio 1143) with other pro-apoptotic agents, which can potentially bring huge benefits to patients by enhancing the efficiency of the treatment."
"Ascenta is pleased to form this partnership with Debiopharm, a company that has demonstrated a commitment to and expertise in the development of medicines to help cancer patients", noted Dr. Mel Sorensen, President and CEO of Ascenta.
AT-406 is an orally available small molecule that neutralizes major inhibitors of apoptosis. Apoptosis, or "programmed cell death," is a precisely regulated, complex process ensuring that defective, damaged or superfluous cells are eliminated. Evasion of apoptosis is a hallmark of cancer, enabling cancer cells to live indefinitely and grow uncontrollably. Most current cancer therapies
|SOURCE The Debiopharm Group|
Copyright©2010 PR Newswire.
All rights reserved